Aptamer Group

Aptamer Group Aptamer Group is the developer of Optimer® binders to enable innovation in the life science industr

Aptamer Group develops Optimer® binders to enable innovation in the life science industry. Optimer binders are oligonucleotide-based affinity binders for use in research, diagnostics, therapeutics and bioprocessing. Combining high target affinity and selectivity, with an expanded target range and the highest batch consistency the fully in vitro Optimer discovery and development platform is supporting new and improved solutions.

Do you need cheaper reagents? Better performing reagents? More consistent reagents for reproducible results?If you need ...
03/09/2026

Do you need cheaper reagents? Better performing reagents? More consistent reagents for reproducible results?

If you need more from your flow cytometry reagents, check out our blog on aptamers in flow cytometry and get in touch to see how we can help you get reliable data for even your toughest targets.
https://aptamergroup.com/aptamer-applications-flow-cytometry/

If you need a reagent that performs in cell-based assays or on tissue then our Optimer® cell discovery process uses cell...
24/08/2026

If you need a reagent that performs in cell-based assays or on tissue then our Optimer® cell discovery process uses cells as target material to derisk your development from the start.

See the data behind enhanced IHC reagents, targeted oligonucleotide delivery, and new flow cytometry reagents in our application note.

https://aptamergroup.com/optimer-enhanced-cell-targeting-biomarker-discovery/

A protein-targeted aptamer that binds fabulously in solution doesn't always bind the same target once it's expressed on ...
19/08/2026

A protein-targeted aptamer that binds fabulously in solution doesn't always bind the same target once it's expressed on a cell surface.

This is precisely why we don't rely on a single discovery method.

For applications like flow cytometry and ICC, we combine protein with cell discovery methods to ensure your aptamer binds specifically to the target in its correctly folded, accessible form, not tucked up in a membrane where your reagent can’t see it.

Matching the discovery method to your target and application, rather than using a one-size-fits-all process, measn we overcome that binding in solution and deliver binding where you need it.

https://aptamergroup.com/multiple-discovery-methods-for-aptamers/

⚠️⚠️ We've spotted fake job listings using the Aptamer Group name and logo on sites like Learn4Good, Jobrapido, Jobijoba...
14/08/2026

⚠️⚠️ We've spotted fake job listings using the Aptamer Group name and logo on sites like Learn4Good, Jobrapido, Jobijoba and Expertini. ⚠️⚠️

These are not from us.

All genuine Aptamer Group roles are posted only on our official careers page (aptamergroup.com/careers) and our LinkedIn page. We never ask candidates for money or personal financial info during hiring.

If you spot one of these fake listings, please don't engage. Instead report it to the site and let us know.

Flow cytometry isn't just how we test Optimer reagents. For applications that use whole cells, like flow and ICC, it's b...
06/08/2026

Flow cytometry isn't just how we test Optimer reagents. For applications that use whole cells, like flow and ICC, it's built into how we discover them.

Our FACS-based discovery screens against negative and positive target cells, so cytometry performance is validated during the discovery process, not after.

(We also run dedicated discovery processes for protein and small-molecule targets.)

Reagent works on protein in solution but not on the cell surface? It's a common gap between affinity ligand discovery an...
04/08/2026

Reagent works on protein in solution but not on the cell surface? It's a common gap between affinity ligand discovery and real assay performance.

Optimer development includes screening against whole cells to assess binding in native format, validating against positive and null-expressing cells as part of the process, so specificity is proven before you get the reagent.

https://aptamergroup.com/derisk-aptamer-selection-with-cell-screening/

August 1st is , and we are here for celebrating all the sciencey goodness of RNA, along with the researchers and clinic...
31/07/2026

August 1st is , and we are here for celebrating all the sciencey goodness of RNA, along with the researchers and clinicians bringing it to life. 🧬

RNA has come a long way from being merely the middleman in the central dogma of molecular biology. Today, it is a versatile, scalable tool in the modern medicine chest, driving innovations from lifesaving vaccines and N-of-1 personalised therapies to reagents that could deliver the next big breakthrough.

At Aptamer Group, we use our Optimer platform to develop synthetic DNA and RNA binders as antibody alternatives to help you pursue tricky targets, deliver therapeutics precisely, and build better assays.

Here’s a snapshot of how our RNA Optimers are currently being explored:

🎯 Targeted Delivery: Getting therapeutics, like siRNA, directly into target cells and helping them avoid the endosome.

📊 Bioanalytical & QC Assays: Supporting PK profiling, biomarker discovery, and critical manufacturing monitoring.

From discovery to delivery, we’re thrilled to collaborate with academic leaders and biopharmaceutical pioneers pushing the boundaries of what RNA can do.

Optimers can inhibit enzyme activity or disrupt protein-protein interactions, with the specificity to hit function-defin...
23/07/2026

Optimers can inhibit enzyme activity or disrupt protein-protein interactions, with the specificity to hit function-defining sites that small molecules often can't reach.
See this in action in our new application note on KOD DNA Polymerase. Optimer® inhibitors show high specificity and temperature-sensitive hot-start control for accurate and clean PCR and NGS.
Same platform, any enzyme target or any PPI you need to break.

Download the app note: https://aptamergroup.com/optimer-hot-start-kod-dna-polymerase/

Our panel of Optimer® binders has been developed and validated and is ready to integrate into your platform. https://apt...
20/07/2026

Our panel of Optimer® binders has been developed and validated and is ready to integrate into your platform.

https://aptamergroup.com/optimer-binders/optimer-binders/

Targeting small molecules (cortisol, folic acid, imatinib, irinotecan) and proteins (SARS-CoV-2 spike domains, gp120, KOD DNA Polymerase, and more).

✅ Trial in your own lab before you commit or use freely for research
✅ License for your commercial processes
✅ Custom functional group modifications for simple integration
✅ Validated via ELISA, SPR, biolayer interferometry, and nanopore biosensing

Need a target that's not on the list? Our custom development service can build one for you.

14/07/2026

How does a single reagent completely shut down two entirely different enzymatic functions? It all comes down to a unique binding mode.

Our Optimer® inhibitor engages simultaneously with both the exonuclease and polymerase domains of KOD. By physically interacting with both domains at once, a single Optimer reagent delivers complete inhibition at ambient temperatures, preventing premature extension and template degradation, for reliable PCR results.

Watch the final clip in our series to see the structural story unfold and get in touch to see how custom enzyme inhibition with Optimer could support your research.

Address

Windmill House, Innovation Way, Heslington
York
YO105BR

Website

Alerts

Be the first to know and let us send you an email when Aptamer Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Aptamer Group:

Shortcuts

Share

Category